Genetic polymorphisms of surfactant protein D rs2243639, interleukin (IL)-1β rs16944 and IL-1RN rs2234663 in chronic obstructive pulmonary disease, healthy smokers, and non-smokers

Molecular Diagnosis and Therapy

Volumn 18, Issue 3, 2014, Pages 343-354

  Issac, Marianne Samir M ^a   Ashur, Wafaa ^a   Mousa, Heba ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; SURFACTANT PROTEIN D;

ADULT; AGED; ALLELE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; SPIROMETRY; VARIABLE NUMBER OF TANDEM REPEAT; BLOOD; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; MIDDLE AGED;

ADULT; AGED; CASE-CONTROL STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HAPLOTYPES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MINISATELLITE REPEATS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RESPIRATORY FUNCTION TESTS; SMOKING;

EID: 84902365919     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0084-5     Document Type: Article

References (66)

1. Stewart JI, Criner GJ. The small airways in chronic obstructive pulmonary disease: pathology and effects on disease progression and survival. Curr Opin Pulm Med. 2013;19(2):109-15.
2. ATS Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: definitions, epidemiology, pathophysiology, diagnosis, and staging. Am J Respir Crit Care Med 1995;152:S78-S83.
3. Ishii T, Matsuse T, Teramoto S, et al. Neither IL-1b, IL-1 receptor antagonist, nor TNF-α polymorphisms are associated with susceptibility to COPD. Respir Med. 2000;94:847-51.
4. Ishii T, Hagiwara K, Kamio K, et al. Involvement of surfactant protein D in emphysema revealed by genetic association study. Eur J Hum Genet. 2012;20:230-5.
5. McCloskey SC, Patel BD, Hinchliffe SJ, et al. Siblings of patients with severe obstruction pulmonary disease have a significant risk of airflow obstruction.AmJ Respir Crit CareMed. 2001;164:1419-24. (Pubitemid 33124020)
6. Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol. 2005;42:279-87. (Pubitemid 39626759)
7. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest. 2002;109:707.
8. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol. 2001;63:521.
9. Nadesalingam J, Reid KB, Palaniyar N. Collectin surfactant protein D binds antibodies and interlinks innate and adaptive immune systems. FEBS Lett. 2005;579:4449-53. (Pubitemid 41116380)
10. Guo CJ, Atochina-Vasserman EN, Abramova E, et al. S-nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol. 2008;6(11):e266. doi:10.1371/journal.pbio.0060266.
11. Gardai SJ, Xiao YQ, Dickinson M, et al. By binding SIRP alpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell. 2003;115(1):13-23. (Pubitemid 37255314)
12. Stahlman MT, Gray ME, Hull WM, et al. Immunolocalization of surfactant protein-D (SP-D) in human fetal, newborn, and adult tissues. J Histochem Cytochem. 2002;50:651.
13. Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med. 1999;159:646.
14. Leth-Larsen R, Nordenbaek C, Tornoe I, et al. Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia small star, filled. Clin Immunol. 2003;108:29.
15. Glas J, Beynon V, Bachstein B, et al. Increased plasma concentration of surfactant protein D in chronic periodontitis independent of SFTPD genotype: potential role as a biomarker. Tissue Antigens. 2008;72:21-8. (Pubitemid 351841643)
16. Crouch E, Rust K, Veile R, et al. Genomic organization of human surfactant protein D (SP-D). SP-D is encoded on chromosome 10q22.2-23.1. J Biol Chem. 1993;268:2976-83. (Pubitemid 23057937)
17. Lin Z, Pearson C, Chinchilli V, et al. Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS. Clin Genet. 2000;58:181-91.
18. Shakoori TA, Sin DD, Bokhari SN, et al. SP-D polymorphisms and the risk of COPD. Dis Markers. 2012;33(2):91-100. doi:10.3233/DMA-2012-0909.
19. Vandivier RW, Ogden CA, Fadok VA, et al. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol. 2002;169:3978-86.
20. Park JW, Ryter SW, Choi AM. Functional significance of apoptosis in chronic obstructive pulmonary disease. COPD. 2007;4:347-53. (Pubitemid 350135869)
21. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J. 2009;34:95-102.
22. Brandolini L, Sergi R, Caselli G, et al. Interleukin-1 beta primes interleukin-8-stimulated chemotaxis and elastase release in human neutrophils via its type I receptor. Eur Cytokine Network. 1997;8:173-8. (Pubitemid 28152143)
23. Tsang YT, Neelamegham S, Hu Y, et al. Synergy between L-selectin signaling and chemotactic activation during neutrophil adhesion and transmigration. J Immunol. 1997;159:4566-77. (Pubitemid 127470619)
24. Conca W, Kaplan PB, Krane SM. Increases in levels of procollagenase messenger RNA in cultured fibroblasts induced by human recombinant interleukin 1 beta or serum follow c-jun expression and are dependent on new protein synthesis. J Clin Invest. 1989;83:1753-7. (Pubitemid 19124135)
25. D'Armiento J, Dalal SS, Okada Y, et al. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell. 1992;71:955-61.
26. Serdaroglu GS, Alpman A, Tosun A, et al. Febrile seizures: interleukin 1β and interleukin-1 receptor antagonist polymorphisms. Pediatr Neurol. 2009;40:113-6.
27. Kira R, Torisu H, Takemoto M, et al. Genetic susceptibility to simple febrile seizures: interleukin-1beta promoter polymorphisms are associated with sporadic cases. Neurosci Lett. 2005;384:239-44. (Pubitemid 40836007)
28. Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (Global strategy for diagnosis, management, and prevention of COPD). http://www.goldcopd.com/ (updated 2013). Accessed 10 Sep 2013
29. American Thoracic Society. Standardization of spirometry. Am J Respir Crit Care Med. 1994;152:1107-36.
30. Alagappan R. Smoking and cardiovascular disease. In: Alagappan R, editor. Manual of practical medicine. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2002. p. 562-3.
31. Zhang D, Zheng H, Zhou Y, et al. Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer. BMC Cancer. 2007;7:45. doi:10.1186/1471-2407-7-45.
32. Barnes PJ, Celi BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165-85.
33. Hersh CP, DeMeo DL, Lange C, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol. 2005;33:71-8. (Pubitemid 40961016)
34. Guo X, Lin H-M, Lin Z, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J. 2001;18:482-90. (Pubitemid 32895633)
35. Thomas NJ, DiAngelo S, Hess JC, et al. Transmission of surfactant protein variants and haplotypes in children hospitalized with respiratory syncytial virus. Pediatr Res. 2009;66(1):70-3. doi:10.1203/PDR.0b013e3181a1d768.
36. Ampuero S, Luchsinger V, Tapia L, et al. SP-A1, SP-A2 and SP-D gene polymorphisms in severe acute respiratory syncytial infection in Chilean infants. Infect Genet Evol. 2011;11(6):1368-77.
37. Thomas NJ, Fan R, DiAngelo S, et al. Haplotypes of the surfactant protein genes A and D as susceptibility factors for the development of respiratory distress syndrome. Acta Paediatr. 2007;96:985-9. (Pubitemid 46934441)
38. Krueger M, Puthothu B, Gropp E, et al. Amino acid variants in surfactant protein D are not associated with bronchial asthma. Pediatr Allergy Immunol. 2006;17:77-81.
39. van Diemen CC, Postma DS, Aulchenko YS, et al. Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate. Eur Respir J. 2010;35:768-75. doi:10.1183/09031936.00054408.
40. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672-88. (Pubitemid 37258549)
41. Joos L, McIntyre L, Ruan J, et al. Association of IL-1beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. Thorax. 2001;56:863-6. (Pubitemid 32999834)
42. Hegab AE, Sakamoto T, Saitoh W, et al. Polymorphisms of TNFα, IL1β, and IL1RN genes in chronic obstructive pulmonary disease. Biochem Biophys Res Commun. 2005;329:1246-52. (Pubitemid 40568703)
43. Mei JJ, Liang Y, Shen N, He B. Association between interleukin-1B polymorphisms and chronic obstructive pulmonary disease: a meta-analysis. Zhonghua Yi Xue Za Zhi. 2013;93(12):910-5.
44. Asada M, Yamaya M, Ebihara S, et al. Interleukin-1β gene polymorphisms associated with COPD. Chest. 2005;128:1072-3. doi:10.1378/chest. 128.2.1072. (Pubitemid 41140557)
45. Danilko KV, Korytyna GF, Akhmadishina LZ, et al. Association of polymorphisms of cytokine genes (IL1B, IL1RN, TNFA, LTA, IL6, IL8, and IL10) with chronic obstructive pulmonary disease. Mol Biol. 2007;41(1):22-31. (Pubitemid 46339652)
46. Burgel PR. The role of small airways in obstructive airway diseases. Eur Respir Rev. 2011;20(119):23-33. doi:10.1183/09059180.00010410.
47. Gromova AY, Simbirtsev AS. Polymorphism of human genes of the IL-1 family. Tsitokiny Vospal. 2005;4:3-12.
48. Jeremias J, Ledger WJ, Witkin SS. Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis. Am J Obstet Gynecol. 2000;182:283-5. (Pubitemid 30127336)
49. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology. 1994;106:637-42.
50. Tarlow JK, Clay FE, Cork MJ, et al. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Investig Dermatol. 1994;103:387-90. (Pubitemid 24329762)
51. Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993;91:403-4. (Pubitemid 23177503)
52. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1RA) plasma levels are co-ordinately regulated by both IL-1RA and IL-1beta genes. Eur J Immunol. 1998;28:2598-602. (Pubitemid 28362734)
53. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 1995;99:303-10.
54. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol. 1998;47:195-8. (Pubitemid 28153395)
55. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328:106-13.
56. Winkler C, Atochina-Vasserman EN, Holz O, et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res. 2011;12:29. doi:10.1186/1465-9921-12-29.
57. Ozyurek BA, Ulasli SS, Bozbas SS. Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease. Multidiscipl Respir Med. 2013;8(36):1-7.
58. Sørensen GL, Hjelmborg JvB, Kyvik KO, et al. Genetic and environmental influences of surfactant protein D serum levels. Am J Physiol Lung Cell Mol Physiol. 2006;290:1010-7. doi:10.1152/ajplung.00487.2005.
59. Betsuyaku T, Kuroki Y, Nagai K, et al. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J. 2004;24:964-70. (Pubitemid 39642287)
60. Foreman MG, Kong X, Demeo DL, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2011;44:316-22.
61. Leth-Larsen R, Garred P, Jensenius H, et al. A common polymorphism in the SFTPD gene influences assembly, function, and concentration of surfactant protein D. J Immunol. 2005;174:1532-8.
62. Heidinger K, König IR, Bohnert A, et al. Polymorphisms of the human surfactant protein-D (SFTPD) gene: strong evidence that serum levels of surfactant protein-D (SP-D) are genetically influenced. Immunogenetics. 2005;57:1-7. (Pubitemid 40591241)
63. He Y, Crouch EC, Rust K, et al. Proximal promoter of the surfactant protein D gene: regulatory roles of AP-1, forkhead box, and GT box binding proteins. J Biol Chem. 2000;275:31051-60.
64. Rust K, Bingle L, Mariencheck W, et al. Characterization of the human surfactant protein D promoter: transcriptional regulation of SP-D gene expression by glucocorticoids. Am J Respir Cell Mol Biol. 1996;14:121-30. (Pubitemid 126441384)
65. Shakoori TA, Sin DD, Ghafoor F, et al. Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease. Disease Markers. 2009;27:287-94. doi:10.3233/DMA-2009-0674.
66. Engströma G, Lindberg C, Gerhardsson de Verdier M, et al. Blood biomarkers and measures of pulmonary function: a study from the Swedish twin registry. Respir Med. 2012;106:1250-7.